MedPath

NEUROBIOLOGICAL TECHNOLOGIES

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:0

Trial Phases

1 Phases

Phase 3:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 3
2 (100.0%)

ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke

Phase 3
Terminated
Conditions
Stroke
Cerebral Ischemia
Brain Infarction
Interventions
Biological: Ancrod (Viprinex)
Drug: Placebo
First Posted Date
2006-03-08
Last Posted Date
2010-01-12
Lead Sponsor
Neurobiological Technologies
Target Recruit Count
311
Registration Number
NCT00300196
Locations
🇺🇸

Enloe Medical Center, Chico, California, United States

🇺🇸

UCSF-Fresno, Fresno, California, United States

🇺🇸

Sherry Braheny MD - A Prof. Corporation, La Mesa, California, United States

and more 89 locations

Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke

Phase 3
Terminated
Conditions
Brain Infarction
Stroke
Cerebral Ischemia
Interventions
First Posted Date
2005-09-01
Last Posted Date
2009-12-23
Lead Sponsor
Neurobiological Technologies
Target Recruit Count
277
Registration Number
NCT00141011
Locations
🇺🇸

Mayo Clinic Hospital / Arizona, Phoenix, Arizona, United States

🇺🇸

Sparks Regional Medical Center, Fort Smith, Arkansas, United States

🇺🇸

Loma Linda University School of Medicine, Loma Linda, California, United States

and more 97 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.